- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03060759
Light Therapy as Treatment for Fatigue in Multiple Sclerosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Protocol:
Eligible participants will be consented and randomized 1:1 to (a) white LT (10,000 lux), or (b) dim red LT (<300 lux). Participants will be informed that this study will examine the effect of two different light spectra on fatigue. The following assessments will be administered by the study principal investigator at the baseline visit: (1) the Kurtzke Extended Disability Status Scale (EDSS), (2) FSS, (3) Beck Depression Inventory II (BDI), (4) Pittsburgh Sleep Quality Index (PSQI), (5) Berlin questionnaire for obstructive sleep apnea, (6) Epworth Sleepiness Scale. A two-week sleep diary will be collected before enrollment in order to screen for significant behavioral insufficient sleep or circadian rhythm disorders. The light box used for LT is designed to stand on a desk or tabletop. It can be used in the home or office. The light is delivered at a downward angle to maximize the effectiveness. The box runs on 124 watts and contains full spectrum 5000k 10,000 lux bulbs. Bright light treatment requires at least 2,500 lux to be effective.
Data Collection:
The study period will include a two-week baseline period, a four-week treatment period, and a four-week follow up period. Throughout the study period, participants will record their fatigue using the Visual Analogue Fatigue Scale (VAFS) four times daily, starting after waking up, and every four hours thereafter. The VAFS is a simple, validated 10-point scale ranging from 1 to 10 in which participants can report their fatigue as a snapshot at that particular moment. Data collection will occur by participants in self-report fashion. A FSS score will be collected at enrollment as well as at the end of the four week treatment period and the end of the four week follow-up period. There will be three visits with a principal investigators (PI), including the baseline visit described above, a visit with the PI at the end of the treatment period in which participants will report a FSS and discuss their experiences with LT, and a third follow-up visit at the end of the four-week follow up period for a final FSS. At this last visit they will be queried on whether they believe the intervention had any effect on their fatigue and whether they believe the alternative therapy (white light or dim red light) would have been more or less beneficial. Additionally participants will be asked to keep a LT log in which they will record daily LT exposure and associated side effects.
Statistical Analysis:
The primary outcome measure is the change in the average FSS after the four-week study period in the bright light "active" vs. dim light "control" groups. There are no reports on FSS in response to bright LT in pMS. Using the conventional values of α=0.05 and β=0.80 for 2-tailed tests of probability with equally sized groups: a difference in 10 points on FSS between groups requires 18 people per study arm; a difference in 8 points requires 28 people per group. If power is reduced to 70%, the sample sizes are 22 and 14 for 8-point and 10-point differences. First, the investigators will compare the mean change in FSS scores, from baseline to after completion of LT, in an intention to treat analysis. The secondary outcome measure will be a change in the global VAFS scores after light therapy in both groups. Frequencies will be used to describe baseline characteristics across treatment arms. X2 statistics or Fisher's exact test will be used to compare the differences between groups. VAFS will be evaluated using a mixed-effects model which accounts for correlation between repeated measurements. Participant logbooks will be used to generate summary statistics and graphically display fatigue patterns throughout the day. Logbooks will also qualitatively assess the safety and tolerability of LT.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Relapsing remitting Multiple Sclerosis based on the McDonald Criteria (2010)
- Over 18 years old
- Presence of fatigue defined as FSS over 36
Exclusion Criteria:
- A change in an anti-depressant up to 4 weeks prior to study screening
- A change in fatigue medication regime or MS disease modifying therapy up to 4 weeks prior to study screening
- Shift work
- Use of photosensitizing medication
- Presence of eye trauma or acute optic neuritis within the preceding 3 months
- History of traumatic brain injury
- Probable (untreated) sleep apnea based on Berlin questionnaire
- Significant anemia
- History of mania
- MS relapse in the preceding four weeks
- Current pregnancy
- Known light sensitivity
- Other complicating illness preventing study completion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Light Therapy-Spectrum 1
Light from 'active' spectrum
|
The light box used for LT (SunRay by The Sunbox Company, Gaithersburg, Maryland, USA) is approximately 15.5" tall x 23" wide x 3.25" deep and is designed to stand on a desk or tabletop.
It can be used both in the home or office.
The light is delivered at a downward angle to maximize the effectiveness.
The box runs on 124 watts and contains full spectrum 5000k 10,000 lux bulbs.
|
Placebo Comparator: Light Therapy-Spectrum 2
Light from 'placebo' spectrum
|
The light box used for LT (SunRay by The Sunbox Company, Gaithersburg, Maryland, USA) is approximately 15.5" tall x 23" wide x 3.25" deep and is designed to stand on a desk or tabletop.
It can be used both in the home or office.
The light is delivered at a downward angle to maximize the effectiveness.
The box runs on 124 watts and contains full spectrum 5000k 10,000 lux bulbs.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Average Fatigue Severity Scale (FSS) Score
Time Frame: 4 weeks
|
Measure of general level of fatigue.
Range: 9 to 63. Lower scores indicate less reported fatigue.
|
4 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016P002696
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis, Relapsing-Remitting
-
BiogenWithdrawnRelapsing-Remitting Multiple Sclerosis | Relapsing Forms of Multiple Sclerosis
-
BiogenAbbVieTerminatedMultiple Sclerosis | Relapsing-Remitting Multiple SclerosisUnited States, Denmark, Italy, United Kingdom, Czechia, Canada, Hungary, Spain, Australia, Israel, Georgia, Serbia, Russian Federation, Ukraine, India, Poland, Brazil, France, Argentina, Germany, Greece, Ireland, Mexico, Moldova, Republic... and more
-
EMD SeronoPfizerCompletedRelapsing-remitting Multiple SclerosisUnited States, United Kingdom, Argentina, Austria, Brazil, France, Germany, Italy, Netherlands, Russian Federation, Spain, Switzerland
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedRelapsing-Remitting Multiple SclerosisUnited States
-
BiogenTerminatedRelapsing-Remitting Multiple SclerosisUnited States, Spain, Germany, Australia, Sweden, Czechia, France, Italy, United Kingdom
-
Novartis PharmaceuticalsWithdrawnMultiple Sclerosis (Relapsing Remitting)
-
Genzyme, a Sanofi CompanyTerminatedRelapsing-remitting Multiple SclerosisSweden, Poland, Russian Federation, United States, Canada
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple SclerosisGermany
-
Mitsubishi Tanabe Pharma CorporationCompletedRelapsing-remitting Multiple SclerosisCroatia, Bulgaria, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Lithuania, Poland, Belgium, Hungary, Serbia, Finland, Ukraine, Switzerland, Canada, Turkey
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisUnited States
Clinical Trials on Light Therapy box
-
University College, LondonAction Medical ResearchUnknown
-
Portland VA Medical CenterCenter for Neuroscience and Regenerative Medicine (CNRM)RecruitingTraumatic Brain InjuryUnited States
-
Second Affiliated Hospital of Soochow UniversityRecruitingParkinson Disease | Sleep Disorder | Circadian Rhythm DisordersChina
-
Thomas Jefferson UniversityApollo Health SystemsCompletedSeasonal Affective DisorderUnited States
-
Rush University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
University of Maryland, BaltimoreNational Institute of Mental Health (NIMH)Completed
-
University of CalgaryCanadian Cancer Society (CCS)Completed
-
Brigham and Women's HospitalUniversity of Pennsylvania; National Space Biomedical Research Institute; The...CompletedFatigue | Sleep | AlertnessRussian Federation
-
Massachusetts General HospitalAmerican Cancer Society, Inc.Terminated
-
Icahn School of Medicine at Mount SinaiNational Cancer Institute (NCI); University of California, San Diego; Hackensack...CompletedQuality of Life | Breast Cancer | Fatigue | Sleep | Mild Cognitive Impairment | Hematopoietic Stem Cell Transplantation | LightUnited States